Market cap
$1,005 Mln
Recently Viewed
Clear AllMarket cap
$1,005 Mln
Revenue (TTM)
$1 Mln
P/E Ratio
--
P/B Ratio
5.2
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$0 Mln
ROE
-0.5 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
-22.9
Debt to Equity
0
Book Value
$--
EPS
$-1.5
Face value
--
Shares outstanding
71,750,148
CFO
$-312.78 Mln
EBITDA
$-396.81 Mln
Net Profit
$-412.29 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Ventyx Biosciences (VTYX)
| 55.0 | 0.4 | 60.6 | 821.1 | -33.0 | -- | -- |
|
BSE Sensex*
| -8.4 | 0.0 | -7.2 | 5.0 | 9.0 | 9.4 | 12.1 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
|---|---|---|---|---|
|
Ventyx Biosciences (VTYX)
| 312.3 | -11.2 | -92.5 | 65.1 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Ventyx Biosciences (VTYX)
|
14.0 | 1,004.5 | 1.5 | -106.6 | -7,919.7 | -50.4 | -- | 5.2 |
| 65.1 | 8,558.8 | 1,091.0 | 202.3 | 31.6 | 31.3 | 38.2 | 15.0 | |
| 65.0 | 7,998.2 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.5 | |
| 44.3 | 11,791.6 | 2,320.1 | 782.6 | 39.0 | 35.5 | 15.8 | 5.3 | |
| 78.6 | 11,760.7 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 259.0 | 7,628.1 | 389.1 | 204.8 | 41.5 | 18.9 | 38.2 | 6.2 | |
| 519.6 | 12,247.2 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 20.8 | |
| 493.5 | 14,077.1 | 2,530.2 | 451.1 | 21.3 | 70.2 | 32.5 | 30.8 | |
| 102.7 | 8,153.4 | 0.0 | -425.4 | -- | -36.7 | -- | 6.6 | |
| 316.1 | 8,644.3 | 0.0 | -303.3 | -- | -45.8 | -- | 10.1 |
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. Its pipeline includes small molecule therapeutics to treat inflammation across... cardiometabolic disorders, neurodegenerative diseases, and inflammatory disorders. The company's portfolio of NLRP3 inhibitors includes VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for Crohn's disease. It is also developing Tamuzimod, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor that is in a Phase 2a trial for patients with early Parkinson's disease and is in a Phase 2 trial for patients with obesity and additional risk factors for cardiovascular disease. Ventyx Biosciences, Inc. was incorporated in 2018 and is headquartered in San Diego, California. As of March 4, 2026, Ventyx Biosciences, Inc. operates as a subsidiary of Eli Lilly and Company. Address: 12790 El Camino Real, San Diego, CA, United States, 92130 Read more
Executive Chairperson
Dr. Sheila K. Gujrathi M.D.
Executive Chairperson
Dr. Sheila K. Gujrathi M.D.
Headquarters
San Diego, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Ventyx Biosciences Inc (VTYX) is $14.00 (NASDAQ) as of 06-Mar-2026 09:30 EDT. Ventyx Biosciences Inc (VTYX) has given a return of -33.05% in the last 3 years.
Since, TTM earnings of Ventyx Biosciences Inc (VTYX) is negative, P/E ratio is not available.
The P/B ratio of Ventyx Biosciences Inc (VTYX) is 5.25 times as on 06-Mar-2026, a 27 premium to its peers’ median range of 4.13 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2024
|
-1.10
|
0.59
|
|
2023
|
-0.76
|
0.60
|
|
2022
|
-15.73
|
4.82
|
|
2021
|
-3.08
|
0.92
|
|
2020
|
--
|
--
|
The 52-week high and low of Ventyx Biosciences Inc (VTYX) are Rs 25.00 and Rs 0.78 as of 11-Apr-2026.
Ventyx Biosciences Inc (VTYX) has a market capitalisation of $ 1,005 Mln as on 06-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Ventyx Biosciences Inc (VTYX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.